Endocarditis following ocrelizumab in relapsing-remitting MS
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Clinical Neurology,Neurology
Reference6 articles.
1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
2. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
3. Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
4. Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman–Sacks endocarditis: a case for antibiotic prophylaxis?
5. Grasseau A , Boudigou M , Le Pottier L , et al . Innate B cells: the archetype of protective immune cells. Clin Rev Allergy Immunol Epub 2019 June 10.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ocrelizumab;Reactions Weekly;2021-08
2. Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry;Scientific Reports;2021-06-25
3. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis;Vaccines;2020-12-26
4. Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?;Expert Review of Neurotherapeutics;2020-10-10
5. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review;Expert Opinion on Drug Safety;2020-08-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3